Upcoming Earnings for Castle Biosciences
Castle Biosciences (NASDAQ:CSTL) is expected to report its quarterly earnings this November. Investors are keenly awaiting this announcement, as it holds the promise of potentially favorable results.
Analysts' Expectations
Analysts predict an earnings per share (EPS) of approximately $-0.44 for the upcoming quarter. Many investors view this as a critical indicator of the company’s future performance, especially focusing on both their earnings report and guidance.
Historically, guidance plays a significant role in influencing stock price movements, so this forthcoming news could be a pivotal moment for Castle Biosciences.
Review of Previous Earnings
Looking back at previous performance, Castle Biosciences surpassed EPS estimates by $0.65 in the last quarter, which led to a noteworthy share price spike of around 32.83% the following day. This achievement provides a context for the current expectations.
Examining past performance can provide insights into seasonal trends and the overall market reception of the company's results. Here are some details on past earnings:
Stock Price Movements
As of late October, shares of Castle Biosciences were priced at $24.21, realizing a decline of about 25.98% over the previous 52 weeks. This trend indicates a challenging period for long-term shareholders, who might be expressing concerns leading to the upcoming earnings release.
Market Sentiments on Castle Biosciences
To understand investor sentiment, analyzing recent ratings from market analysts becomes vital. With a consensus rating of Buy, Castle Biosciences receives a generally favorable outlook. Analysts have set an average 1-year price target of $37.0, suggesting a significant upside of approximately 52.83%.
Peer Competitor Analysis
In the competitive landscape, it's constructive to compare Castle Biosciences with major players like Fulgent Genetics and AMN Healthcare Services. These entities offer a benchmark for assessing Castle's positioning in the market.
- Fulgent Genetics holds a Buy rating and has a 1-year price target of $25.5, indicating a modest upside of 5.33%.
- AMN Healthcare Services has an Outperform rating, with a target suggesting a potential downside of 11.19%.
- InnovAge Holding currently reflects a less favorable outlook with an Underperform rating and a price target suggesting a downside of approximately 79.35%.
Insights on Industry Standing
In evaluating Castle Biosciences against its peers, certain metrics reveal its competitive edge and areas for improvement:
| Company | Consensus | Revenue Growth | Gross Profit | Return on Equity |
|---|---|---|---|---|
| Castle Biosciences | Buy | -0.94% | $68.56M | 1.01% |
| Fulgent Genetics | Buy | 15.17% | $34.44M | -1.69% |
| AMN Healthcare Services | Outperform | -11.14% | $196.40M | -17.57% |
| InnovAge Holding | Underperform | 11.04% | $41.29M | -0.33% |
Notably, Castle Biosciences excels in Gross Profit and Return on Equity when compared to its competitors, although it finds itself in the middle of the pack for Revenue Growth.
Company Overview and Market Insights
Castle Biosciences Inc is at the forefront of molecular diagnostics, focused particularly on testing solutions for skin cancers and related conditions. Their diverse offerings include DecisionDx-Melanoma and DecisionDx-SCC, which assist in assessing risks associated with various cancers.
Financial Health and Trends
Castle Biosciences currently showcases a lower market capitalization relative to peers, hinting at some challenges in maintaining competitiveness. Recent financial reports reveal a concerning revenue trend with a decline of approximately 0.94% in the last quarter.
However, the company’s net margin stands out positively at around 5.25%, suggesting that they are adept at managing costs effectively. This excellence in profitability is reflected in a Return on Equity of 1.01%, showcasing their capability of utilizing equity capital efficiently.
Debt Management Approach
Another crucial aspect of Castle Biosciences’ financial performance is its relatively low debt-to-equity ratio of 0.08, signifying prudent debt management. This healthy balance is often appreciated by investors concerned about long-term sustainability.
Frequently Asked Questions
What is the expected earnings per share for Castle Biosciences?
Analysts anticipate an EPS of approximately $-0.44 for the upcoming earnings report.
How did Castle Biosciences perform in the last quarter?
In the last quarter, the company beat EPS estimates by $0.65, causing a significant share price increase.
What is the current stock price of Castle Biosciences?
As of late October, shares were trading at approximately $24.21.
How does Castle Biosciences compare to its peers?
Castle scores well in Gross Profit and Return on Equity compared to its peers but faces challenges in revenue growth.
What are the company's key products?
The company's primary offerings include risk stratification tests for skin cancers, among others.
